Although the sequence of the AAV inverted terminal repeat has been known for 40 years, there are still unanswered questions about functions attributable to the terminal 125 nucleotides.
Get full access to this article
View all access options for this article.
References
1.
CarterBJ, FifeKH, de la MazaLM, et al.Genome localization of adeno-associated virus RNA. J Virol, 1976; 19:1044–1053.
2.
OstroveJM, DuckworthDH, BernsKI. Inhibition of adenovirus-transformed cell oncogenicity by adeno-associated virus. Virology, 1981; 113:521–533.
3.
de la MazaLM, CarterBJ. Inhibition of adenovirus oncogenicity in hamsters by adeno-associated virus DNA. J Natl Cancer Inst, 1981; 67:1323–1326.
4.
SpearIS, FifeKH, HauswirthWW, et al.Evidence for two nucleotide sequence orientations within the terminal repetition of adeno-associated virus DNA. J Virol, 1977; 24:627–634.
5.
KoczotFJ, CarterBJ, GaronCF, et al.Self-complementarity of terminal sequences within plus or minus strands of adenovirus-associated virus DNA. Proc Natl Acad Sci U S A, 1973; 70:215–219.
6.
LusbyE, FifeKH, BernsKI. Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA. J Virol, 1980; 34:402–409.
7.
Cavalier-SmithT. Palindromic base sequences and replication of eukaryote chromosome ends. Nature, 1974; 250:467–470.
8.
LabowMA, HermonatPL, BernsKI. Positive and negative autoregulation of the adeno-associated virus type 2 genome. J Virol, 1986; 60:251–258.
9.
NiTH, McDonaldWF, ZolotukhinI, et al.Cellular proteins required for adeno-associated virus DNA replication in the absence of adenovirus coinfection. J Virol, 1998; 72:2777–2787.
10.
RyanJH, ZolotukhinS, MuzyczkaN. Sequence requirements for binding of Rep68 to the adeno-associated virus terminal repeats. J Virol, 1996; 70:1542–1553.
11.
JulienL, ChassagneJ, PeccateC, et al.RFX1 and RFX3 transcription factors interact with the D sequence of adeno-associated virus inverted terminal repeat and regulate AAV transduction. Sci Rep, 2018; 8:210.
12.
HauswirthWW, BernsKI. Origin and termination of adeno-associated virus DNA replication. Virology, 1977; 78:488–499.
13.
SrivastavaA. Replication of the adeno-associated virus DNA termini in vitro. Intervirology, 1987; 27:138–147.
14.
KotinRM, BernsKI. Organization of adeno-associated virus DNA in latently infected Detroit 6 cells. Virology, 1989; 170:460–467.
15.
KotinRM, LindenRM, BernsKI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J, 1992; 11:5071–5078.
16.
KotinRM, MenningerJC, WardDC, et al.Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics, 1991; 10:831–834.
17.
KotinRM, SiniscalcoM, SamulskiRJ, et al.Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A, 1990; 87:2211–2215.
18.
SamulskiRJ, ZhuX, XiaoX, et al.Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J, 1991; 10:3941–3950.
19.
CheungAK, HogganMD, HauswirthWW, et al.Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J Virol, 1980; 33:739–748.
20.
BohenzkyRA, BernsKI. Interactions between the termini of adeno-associated virus DNA. J Mol Biol, 1989; 206:91–100.
21.
SamulskiRJ, BernsKI, TanM, et al.Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A, 1982; 79:2077–2081.
22.
SamulskiRJ, SrivastavaA, BernsKI, et al.Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell, 1983; 33:135–143.
23.
BohenzkyRA, LeFebvreRB, BernsKI. Sequence and symmetry requirements within the internal palindromic sequences of the adeno-associated virus terminal repeat. Virology, 1988; 166:316–327.
FiersW, ContrerasR, HaegemannG, et al.Complete nucleotide sequence of SV40 DNA. Nature, 1978; 273:113–120.
26.
SrivastavaA, LusbyEW, BernsKI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol, 1983; 45:555–564.
27.
GrossmanZ, WinocourE, BernsKI. Recombination between simian virus 40 and adeno-associated virus: virion coinfection compared to DNA cotransfection. Virology, 1984; 134:125–137.
28.
BainbridgeJW, TanMH, AliRR. Gene therapy progress and prospects: the eye. Gene Ther, 2006; 13:1191–1197.
29.
CideciyanAV, AlemanTS, BoyeSL, et al.Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A, 2008; 105:15112–15117.
30.
HauswirthWW, AlemanTS, KaushalS, et al.Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther, 2008; 19:979–990.
31.
MaguireAM, SimonelliF, PierceEA, et al.Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med, 2008; 358:2240–2248.
32.
MiesbachW, MeijerK, CoppensM, et al.Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood, 2018; 131:1022–1031.
33.
NathwaniAC, RosalesC, McIntoshJ, et al.Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther, 2011; 19:876–885.
34.
GeorgeLA, SullivanSK, GiermaszA, et al.Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med, 2017; 377:2215–2227.
35.
PasiKJ, RangarajanS, MitchellN, et al.Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med, 2020; 382:29–40.
36.
RangarajanS, WalshL, LesterW, et al.AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med, 2017; 377:2519–2530.
37.
GaudetD, MethotJ, DeryS, et al.Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther, 2013; 20:361–369.
38.
MendellJR, Al-ZaidyS, ShellR, et al.Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med, 2017; 377:1713–1722.
DonsanteA, VoglerC, MuzyczkaN, et al.Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther, 2001; 8:1343–1346.
41.
DonsanteA, MillerDG, LiY, et al.AAV vector integration sites in mouse hepatocellular carcinoma. Science, 2007; 317:477.
42.
NaultJC, DattaS, ImbeaudS, et al.Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet, 2015; 47:1187–1193.
43.
BernsKI, ByrneBJ, FlotteTR, et al.Adeno-associated virus type 2 and hepatocellular carcinoma?. Hum Gene Ther, 2015; 26:779–781.
44.
SchmidtM, Gil-FarinaI, BuningH. Reply to Wild-type AAV insertions in hepatocellular carcinoma do not inform debate over genotoxicity risk of vectorized AAV. Mol Ther, 2016; 24:661–662.
45.
LoganGJ, DaneAP, HallwirthCV, et al.Identification of liver-specific enhancer-promoter activity in the 3′ untranslated region of the wild-type AAV2 genome. Nat Genet, 2017; 49:1267–1273.
46.
LindenRM, WardP, GiraudC, et al.Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A, 1996; 93:11288–11294.
47.
LindenRM, WinocourE, BernsKI. The recombination signals for adeno-associated virus site-specific integration. Proc Natl Acad Sci U S A, 1996; 93:7966–7972.
48.
DayaS, CortezN, BernsKI. Adeno-associated virus site-specific integration is mediated by proteins of the nonhomologous end-joining pathway. J Virol, 2009; 83:11655–11664.
49.
HollidayR. The induction of mitotic recombination by mitomycin C in ustilago and saccharomyces. Genetics, 1964; 50:323–335.
50.
SchneppBC, ChulayJD, YeGJ, et al.Recombinant adeno-associated virus vector genomes take the form of long-lived, transcriptionally competent episomes in human muscle. Hum Gene Ther, 2016; 27:32–42.
51.
SchneppBC, ClarkKR, KlemanskiDL, et al.Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol, 2003; 77:3495–3504.
52.
SongS, LuY, ChoiYK, et al.DNA-dependent PK inhibits adeno-associated virus DNA integration. Proc Natl Acad Sci U S A, 2004; 101:2112–2116.
53.
SongS, GoudyK, Campbell-ThompsonM, et al.Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther, 2004; 11:181–186.
54.
SongS, MorganM, EllisT, et al.Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci U S A, 1998; 95:14384–14388.
55.
KaiserJ. How safe is a popular gene therapy vector?. Science, 2020; 367:131.
